[The bronchodilatory effect of fenoterol-HBr in comparison to the new beta2-bronchodilator (NAB 365, clenbuterol-HCl) (author's transl)].
The effect of 4-amino-alpha-[(tert.-butylamino)methyl]-3,5-dichlorobenzyl alcohol hydrochloride (clenbuterol-HCl NAB 365, Spiropent) in comparison to fenoterol HBr was tested in a doubleblind trial in 30 patients with asthma bronchiale. 3 times daily for 7 days 15 patients inhaled 24 microgram NAB 365 or 5 mg fenoterol HBr respectively. The bronchospasmolytical effect proved optimal as one day after inhalation both test groups showed a significant decrease of resistance in the respiratory system. A quantitative difference of efficacy between the tested bronchodilators did not materialize.
D000328:Adult; D000336:Aerosols; D001249:Asthma / Q000503:physiopathology; D001993:Bronchodilator Agents; D002976:Clenbuterol / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000336:Aerosols; D001993:Bronchodilator Agents; D004983:Ethanolamines; D005280:Fenoterol; D002976:Clenbuterol
Die bronchodilatatorische Wirkung von Fenoterol-HBr im Vergleich zu einem neuen beta2-Bronchodilator (NAB 365, Clenbuterol-HCl).